Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116532 · ClinicalTrials.gov registry record · Phase 4
Escitalopram for the Treatment of Obsessive Compulsive Disorder (OCD)
A Phase 4 study of Obsessive - Compulsive Disorder, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00116532: Completed Phase 4 study of Obsessive - Compulsive Disorder, sponsored by Massachusetts General Hospital.
NCT00116532 is a Phase 4 study of Obsessive - Compulsive Disorder that has completed, run by Massachusetts General Hospital. The registered enrollment target is 30 participants, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00116532, a Phase 4 study of Obsessive - Compulsive Disorder, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the efficacy of Escitalopram in the treatment of obsessive compulsive disorder and to determine the optimal treatment dose.
Conditions Studied
Interventions
- DRUG Escitalopram
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - OCD Clinic - Charlestown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2002-10 |
| Est. Completion | 2007-02 |
| Phase | Phase 4 |
What the finished NCT00116532 record still lists
NCT00116532 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Obsessive - Compulsive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Escitalopram is the first listed.
NCT00116532 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00116532 about?
NCT00116532 is a clinical study titled "Escitalopram for the Treatment of Obsessive Compulsive Disorder (OCD)". The purpose of this study is to assess the efficacy of Escitalopram in the treatment of obsessive compulsive disorder and to determine the optimal treatment dose.
What is the current status of trial NCT00116532?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2002-10. Estimated completion is 2007-02.
What conditions does trial NCT00116532 study?
This clinical trial studies the following conditions: Obsessive - Compulsive Disorder.
What interventions are being tested in trial NCT00116532?
The interventions under investigation include: Escitalopram (DRUG).
Who is sponsoring clinical trial NCT00116532?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00116532 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obsessive - Compulsive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00116532's enrollment target sits among peer trials
30 57th of 84 higher than 21 of 84 other Obsessive - Compulsive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obsessive - Compulsive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effectiveness of Deep Brain Stimulation for Treating People With Treatment Resistant Obsessive-Compulsive Disorder
ACTIVE NOT RECRUITING · Phase 4
-
Treatment of Obsessive-Compulsive Disorder
COMPLETED · Phase 4
-
Predicting Treatment Response in Patients With OCD
COMPLETED · Phase 4
-
Transcranial Magnetic Stimulation and Psychotherapy for Treating Obsessive-Compulsive Disorder
RECRUITING · NA
-
Mechanisms of Exposure Therapy for OCD
RECRUITING · NA
-
Using Personalized Assessments in the Treatment of Childhood OCD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia